MTOR and neoplasm: ERBB2 mutations were identified in 5/41 CDK4/6-resistant tumor [37], and preclinical work demonstrated that ERBB2 mutation activates downstream MAPK/AKT/mTOR and confers resistance to CDK4/6 blockade in breast cancer cells [44].